EpiCept, Maxim Pharmaceuticals deal

EpiCept will acquire MAXM for about 5.6 million shares that EpiCept valued at $136 million. EpiCept shareholders will own about 72% of the combined company, and MAXM stockholders will own the remaining 28%. The company will be called EpiCept and will trade on NASDAQ and the Stockholm Stock Exchange. EpiCept's Jack Talley will remain CEO, and MAXM's VP of R&D, Ben Tseng, will be CSO. Wachovia Securities advised EpiCept, while Piper Jaffray advised MAXM. The deal is expected to close during the fourth quarter. ...